. 2023 Apr 8;149(10):8117–8129. doi: 10.1007/s00432-023-04735-w

Table 5.

Frequency of commonly reported adverse events

	Mulvihill et al. (2001)	Hecht et al. (2003)	Lee et al. (2020)			Barton et al. (2021)	Bazan-Peregrino et al. (2021)		Garcia-Carbonero et al. (2022)
	Mulvihill et al. (2001)	Hecht et al. (2003)	Lee et al. (2020)			Barton et al. (2021)	Bazan-Peregrino et al. (2021)		Part 2	Part 3
Dose (viral particles)	All	All	1 × 10¹¹	3 × 10¹¹	1 × 10¹²	All	1 × 10¹⁰	1 × 10¹¹	All	All
Fever/flu-like illness (%)	78	NR	0	0	66	50	50	50	67	86
Asthenia (%)	74	NR	NR	NR	NR	75	100	67	50	21
Thrombocytopaenia (%)	NR	NR	0	0	0	8	0	33	58	14
Anaemia (%)	22	NR	0	0	0	33	50	0	NR	NR
Leukopaenia (%)	21	NR	0	0	0	17	0	17	NR	NR
Nausea (%)	61	NR	0	0	0	67	0	33	25	21
Increased hepatic enzymes (%)	21	NR	NR	NR	NR	58	50	33	17	29

When the percentage of patients experiencing adverse events was not reported, the number of adverse events was divided by the number of patients to give an approximation

NR, not reported